Professor Andrew Hughes MA MB ChB MRCP FFPM PhD
Professor of Translational Medicine
- Email: andrew.hughes@astrazeneca.com
- Telephone: +44 787 9435179
Mereside
Alderley Park
AstraZeneca Pharmaceuticals
Macclesfield
SK10 4TG
Role
Co-lead on Experimental Therapeutics in support of BRC
MCRC Steering Group member; architect in Human Tissue Bank and Pre-operative Trials. Co-supervisor of CRUK and Wellcome CLinical fellowship schemes; and Co-Director of MRes in Translational Medcine.
Dual appointment with AstraZeneca- head of Discovery Medicine
Memberships of Committees and Professional Bodies
American Society of Clinical Oncology
Fellow Faculty Pharmaceutical Physicians
American Association of Cancer Research
British Pharmacological Society
Board member, NCRI
Board Member, ABPI Cancer group
Research
Biomarkers in cancer research
Target linkage in cancer research
Early clinical trials of novel cancer treatments
Methodological Knowledge
Phase O trials
Microdosing
eIND studies
Biomarker qualification
Teaching
MRes Translational Medicine
PhD clinical fellowships with CRUK and Wellcome
Qualifications
MA Anatomy, Cambridge
PhD Neurosciences, CAmbridge
MB ChB (Hons), Manchester
MRCP, Royal College Physicians, London
FFPM, Royal College Physicians, London
Selected publications
2006
- Hughes A. (2006) WO 2006/056760: The use of an endothelin antagonist in combination with an anti-mitotic chemotherapeutic agent in the treatment of cancer. further details
2004
- Hughes A. (2004) W0 2004/035057 A1: The use of a combination of an endothelin antagonist with an EGFR tyrosine kinase antagonist in the treatment of cancer. further details
- Hughes A. (2004) WO 2004/018044 A2: The use of antagonists of the endothelin receptor. further details
2002
- Hughes A. (2002) WO 02/072098 A1: The use of antagonists of E-type prostaglandins at the EP1 receptor to lower uric acid. further details